AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, or listings, of claims in this application.

1. (Previously presented) A stable formulation suitable for administration to animals consisting essentially of a combination of levamisole and an avermectin or levamisole and a milbemycin dissolved in a pyrrolidone solvent.

2. (Previously presented) A stable formulation suitable for administration to animals consisting essentially of a combination of levamisole and an avermectin or levamisole and a milbemycin dissolved in a pyrrolidone solvent and a co-solvent selected from the group consisting of glycol ethers.

3. (Previously presented) The stable formulation suitable for administration to animals as claimed in claims 1 or 2, wherein the pyrrolidone solvent is 2-pyrrolidone or N-methyl pyrrolidone.

4. (Previously presented) The stable formulation suitable for administration to animals as claimed in claims 1 or 2, wherein the avermectin or milbemycin is present in the range of between 0.01-5% w/v.

5. (Previously presented) The stable formulation suitable for administration to animals as claimed in claim 4, wherein the avermectin or milbemycin is selected from the group consisting of abamectin, doramectin, eprinomectin, ivermectin and moxidectin.

6. (Previously presented) The stable formulation suitable for administration to animals as claimed in claims 1 or 2, wherein the levamisole is present in the range of between 1-30% w/v.

7. (Previously presented) A stable formulation suitable for administration to animals ~~as~~ consisting essentially of a combination of levamisole and an avermectin or levamisole and a milbemycin dissolved in a pyrrolidone solvent and at least one excipient selected from the group

consisting of dietary supplements, vitamins, mineral, preservatives, stabilisers, flavorants, and co-solvents.

8. (Previously presented) The stable formulation suitable for administration to animals as claimed in claims 1 or 2, wherein the formulation is suitable for topical administration.

9. (Previously presented) The stable formulation suitable for administration to animals as claimed in claims 1 or 2, wherein the formulation is suitable for parenteral administration.

10. (Previously presented) The stable formulation suitable for administration to animals as claimed in claims 1 or 2, wherein the formulation is suitable for oral administration.

11. (Previously presented) A method of treating cattle infected with *Cooperia* or *Ostertagia* by administering a formulation as claimed in claims 1 or 2.